API
< Back to all clusters
[HEALTH] · France, Chile, Argentina, United Kingdom · 2 sources

started · updated

RSV immunization linked to reduced pneumococcal hospitalizations

An observational study published in The Lancet suggests that immunization against Respiratory Syncytial Virus (RSV) may provide additional protection against invasive pneumococcal infections caused by Streptococcus pneumoniae. The study, conducted in France, monitored over 500,000 children born between February 2023 and January 2024. Researchers observed that children who received the monoclonal antibody Nirsevimab experienced a 36% decrease in hospitalizations due to invasive pneumococcal infections.

Global data highlights the impact of various RSV prevention strategies. In Chile, the administration of monoclonal antibodies to newborns has been associated with an estimated 77% drop in RSV-related hospitalizations. In Argentina, maternal vaccination programs led to a 34% reduction in infant hospitalizations in the Buenos Aires region. Additionally, in Scotland, RSV vaccinations for seniors aged 74 to 79 resulted in a 62% decrease in hospitalizations during the 2024-2025 season.

Entities

Streptococcus pneumoniae · The Lancet · World Health Organization · nirsevimab